<div id="readability-page-1"><div><ul> <li>If you are wondering whether Pulse Biosciences at around US$19.21 is priced fairly or if the market is getting ahead of itself, this article walks through what the numbers indicate about its value.</li> <li>The share price has had a mixed run, with a 24.5% decline over the last week, a 34.1% gain over the last month, a 43.5% gain year to date, a 0.7% decline over the last year, a very large 3 year return of around 7x, and a 30.8% decline over five years.</li> <li>Recent news coverage around Pulse Biosciences has focused on its position in the healthcare space and shifting investor expectations. This helps explain why the share price has moved sharply over different time frames. This context matters, because changing sentiment can affect how investors weigh potential future outcomes against the current share price.</li> <li>Right now, our valuation model gives Pulse Biosciences a value score of 0 out of 6. Next, we will look at how different valuation approaches view the stock, and then finish with a more complete way to think about what that means for you as an investor.</li> </ul> <p>Pulse Biosciences scores just 0/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.</p> <h3>Approach 1: Pulse Biosciences Discounted Cash Flow (DCF) Analysis</h3> <p>A Discounted Cash Flow, or DCF, model takes estimates of a company’s future cash flows and discounts them back to today using a required rate of return. This process arrives at an estimate of what the business might be worth now.</p> <p>For Pulse Biosciences, the model used is a 2 Stage Free Cash Flow to Equity approach, based on projected free cash flows in dollars. The latest twelve month free cash flow is a loss of about $54.7 million. Analyst and extrapolated estimates in the model show cash flows staying negative in the near term, then turning positive by 2030, with projected free cash flow of $10 million in that year. Further out, the model extends these projections through 2035 using estimated growth rates.</p> <p>After discounting all those projected cash flows, the DCF model arrives at an estimated intrinsic value of about $2.62 per share. Compared with the current share price of around $19.21, this DCF output suggests the stock is very expensive relative to the cash flows assumed in the model, or in other words, very overvalued.</p> <p><strong>Result: OVERVALUED</strong></p> <p>Our Discounted Cash Flow (DCF) analysis suggests Pulse Biosciences may be overvalued by 633.7%. Discover 53 high quality undervalued stocks or create your own screener to find better value opportunities.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7900ed03-6abe-4aba-9042-cb7f3f3204fc/chart/dcf/query-ZGF0ZT0yMDI2LTAyLTI2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7900ed03-6abe-4aba-9042-cb7f3f3204fc/chart/dcf/query-ZGF0ZT0yMDI2LTAyLTI2"/><figcaption>PLSE Discounted Cash Flow as at Feb 2026</figcaption></figure> <p>Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Pulse Biosciences.</p> <h3>Approach 2: Pulse Biosciences Price vs Book</h3> <p>For companies that are not yet producing consistent profits, P/B is often more useful than P/E because it compares the share price with the accounting value of net assets rather than earnings that may still be negative or volatile.</p> <p>In general, a higher multiple is easier to justify when investors expect stronger growth and see lower risk, while a lower multiple tends to reflect more modest expectations or higher uncertainty. That is why context matters when you look at any headline ratio.</p> <p>Pulse Biosciences currently trades on a P/B of about 16.19x. This sits above the Medical Equipment industry average P/B of about 2.44x and also above the peer group average of around 3.21x. Simply Wall St also uses a proprietary “Fair Ratio” for the preferred multiple, which estimates what a reasonable P/B might be after considering factors such as earnings growth, profit margins, industry, market cap and specific risks.</p> <p>Because the Fair Ratio is tailored to the company, it can give a more focused view than a simple comparison with industry or peer averages. In this case, the actual 16.19x P/B sits above the Fair Ratio used in the model, which points to the shares trading on a richer multiple than that framework would suggest.</p> <p><strong>Result: OVERVALUED</strong></p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7900ed03-6abe-4aba-9042-cb7f3f3204fc/chart/pb-multiple-vs-industry/query-ZGF0ZT0yMDI2LTAyLTI2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7900ed03-6abe-4aba-9042-cb7f3f3204fc/chart/pb-multiple-vs-industry/query-ZGF0ZT0yMDI2LTAyLTI2"/><figcaption>NasdaqCM:PLSE P/B Ratio as at Feb 2026</figcaption></figure> <p>P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 21 top founder-led companies.</p> <h3>Upgrade Your Decision Making: Choose your Pulse Biosciences Narrative</h3> <p>Earlier we mentioned that there is an even better way to think about valuation. On Simply Wall St you can use Narratives, where you write your own story for Pulse Biosciences by linking your expectations for revenue, earnings and margins to a forecast, a fair value and a clear comparison of that fair value with today’s price. This is all within an easy Community tool that millions of investors use, and that automatically updates when new news or earnings arrive. One investor might set a higher fair value around US$30 based on a very optimistic view of thyroid and cardiac adoption, while another might use a lower fair value around US$22 based on more moderate assumptions. You can immediately see how far each view sits from the current price to help you decide what you want to do.</p> <p>Do you think there's more to the story for Pulse Biosciences? Head over to our Community to see what others are saying!</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7900ed03-6abe-4aba-9042-cb7f3f3204fc/chart/quote-price/query-ZGF0ZT0yMDI2LTAyLTI2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7900ed03-6abe-4aba-9042-cb7f3f3204fc/chart/quote-price/query-ZGF0ZT0yMDI2LTAyLTI2"/><figcaption>NasdaqCM:PLSE 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

<p>Pulse Biosciences (PLSE) is currently priced at approximately $19.21, but recent analysis suggests it may be overvalued. The stock has experienced significant volatility, with a 24.5% decline over the past week and a 34.1% gain over the last month. A Discounted Cash Flow (DCF) analysis indicates an intrinsic value of $2.62 per share, suggesting a 633.7% overvaluation. Additionally, the company's Price-to-Book (P/B) ratio stands at 16.19x, significantly higher than industry averages, further indicating overvaluation. Investors are advised to consider these factors when evaluating Pulse Biosciences' stock.</p>

Simplywall

iShares US Medical Devices

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bear 3X

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Health Equip

Pulse Biosciences

ALPS Medical Breakthrough

Is Pulse Biosciences (PLSE) Share Price Justified After Recent Volatility In Healthcare Sentiment